Araştırma özeti
Aşağıdaki metin kaynak makalenin lisansı doğrulanmış orijinal özetidir. cc by
IntroductionAutosomal recessive Parkinson's disease (ARPD) arises from impaired mitophagy due to dysfunction of the PINK1/Parkin pathway, where PINK1-mediated phosphorylation of ubiquitin at Ser65 is essential for pathway activation. However, experimental limitations obscure the effects of disease-associated mutations on intrinsically disordered regions (IDRs) and post-translational modification (PTM) dynamics.MethodsAn integrated computational pipeline was employed to screen 825 PINK1 missense variants, identifying two high-confidence deleterious mutations, T313M and L347P, within the kinase domain. Variant prioritization was complemented by conserved residue, IDR, and PTM analyses, followed by protein-protein docking, molecular dynamics simulations, MM/PBSA binding free-energy calculations, principal component analysis (PCA), and dynamic cross-correlation matrix (DCCM) analysis.ResultsT313M overlapped a conserved phosphorylation site, whereas L347P mapped to conserved active-site residues, with complementary support from IDR analysis. Docking analysis revealed a progressive reduction in binding affinity from the wild type (-88.4 ± 8.2) to L347P (-81.9 ± 3.4) and T313M (-77.4 ± 4.9), accompanied by decreased electrostatic stabilization (-357.6 → -260.6 → -235.5 kcal/mol) and buried surface area (1741.6 → 1624.1 → 1547.4 Å2). Molecular dynamics simulations demonstrated that T313M produced the greatest structural and dynamic perturbations, whereas L347P induced moderate destabilization with increased solvent exposure. Although MM/PBSA analysis indicated broadly comparable binding energetics across all systems, PCA and DCCM analyses revealed increased conformational flexibility and altered residue communication in the mutant complexes, particularly T313M.DiscussionThese findings establish a mechanistic link between mutation-induced structural dynamics and impaired PINK1-ubiquitin recognition at Ser65, providing a mutation-specific framework for understanding early mitophagy impairment in ARPD and supporting future molecular assessment and targeted therapeutic development.
Bilimsel değerlendirme
Araştırma sorusu
Sorunun kapsamı orijinal çalışma üzerinden değerlendirilir.
Yöntem ve örneklem
Çalışma tasarımı ve örneklem için kaynak makaleyi kontrol edin.
Temel bulgular
Bu kayıt için editoryal olarak onaylanmış bulgu özeti henüz yayımlanmadı.
Sınırlılıklar
Sonuçların genellenebilirliği, yanlılık ve klinik anlamı ayrıca incelenmelidir.
Bibliyografik veriden yöntem, örneklem veya klinik sonuç çıkarımı yapılmaz.